191 Results for "

NASH

" in MedChemExpress (MCE) Product Catalog:
Products (191)

191 Results for "NASH" in MCE Product Catalog:

15
15 Publications Verification
Cat. No.: HY-123986
CAS No.: 68003-38-3
Purity:  99.95%
Research Areas:  

Inflammation/Immunology Cancer

CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-109083
CAS No.: 1418274-28-8
Purity:  99.10%
Synonyms: GS-9674
Target:  

FXR Autophagy

Research Areas:  

Inflammation/Immunology

Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-100008
CAS No.: 81485-25-8
Purity:  98.06%
Synonyms: NIK333
Target:  

RAR/RXR SphK Autophagy HCV

Research Areas:  

Infection Cancer

Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1 . Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression . Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-116374
CAS No.: 474-74-8
Purity:  99.90%
Synonyms: Lithocholylglycine
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-116374A
CAS No.: 24404-83-9
Purity:  ≥98.0%
Synonyms: Lithocholylglycine sodium
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

Glycolithocholic acid (Lithocholylglycine) sodium is the sodium salt of Glycolithocholic acid. Glycolithocholic acid is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B2209B
CAS No.: 22465-48-1
Synonyms: Vitamin B12a acetate
Hydroxocobalamin acetate is an injectable natural vitamin B12. Hydroxocobalamin acetate binds to NO. Hydroxocobalamin acetate detoxifies Cyanide and NaSH. Hydroxocobalamin acetate reduces hypotension. Hydroxocobalamin acetate is used in research related to vitamin B12 deficiency, including pernicious anemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-148814
CAS No.: 2894848-07-6
Purity:  99.83%
Target:  

17β-HSD

Research Areas:  

Metabolic Disease

BI 3231, a chemical probe, is a potent and selective hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P3463
CAS No.: 123475-27-4
Synonyms: GLP-1 (human)
Target:  

GCGR

Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-147246
CAS No.: 1868138-66-2
Purity:  99.34%
Synonyms: HTD1801; BUDCA
Research Areas:  

Metabolic Disease

Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108022
CAS No.: 1133819-87-0
Purity:  97.35%
Synonyms: MSDC-0602
Azemiglitazone (MSDC-0602) is an orally active thiazolidinedione (TZD) -like molecule, which binds to PPARγ with low binding and activating affinity. Azemiglitazone inhibits mitochondrial pyruvate carrier (MPC), which inhibits Alzheimer’s disease and diminishes nonalcoholic steatohepatitis (NASH) caused liver injury .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119039
CAS No.: 1110873-99-8
Purity:  99.75%
Target:  

TAM Receptor

Research Areas:  

Inflammation/Immunology Cancer

RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-158127
CAS No.: 3048021-44-6
Purity:  99.95%
Target:  

FABP

FABP1-IN-1 (44) is a selective FABP1 inhibitor, with an IC50 of 4.46 μM. FABP1-IN-1 (44) can be used for the research of NASH .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19522C
CAS No.: 928821-40-3
Synonyms: MBX-8025 (lysine dihydrate); RWJ-800025 (lysine dihydrate)
Seladelpar Lysine dihydrate (MBX-8025 lysine dihydrate) is an orally active, selective PPAR-δ agonist with an EC50 of 2 nM against hPPAR-δ. Seladelpar Lysine dihydrate reduces serum IL-31 and bile acid levels. It alleviates pruritus symptoms. Seladelpar Lysine dihydrate enhances insulin sensitivity, normalizes levels of hyperglycemia, hyperinsulinemia, glucose disposal capacity, serum lipids and hepatic free cholesterol. It reduces steatosis, hepatic inflammation and improves liver fibrosis. Seladelpar Lysine dihydrate reverses the pathological changes of non-alcoholic steatohepatitis (NASH). It is applicable to research related to primary biliary cholangitis and non-alcoholic steatohepatitis (NASH) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-151932
CAS No.: 3037847-72-3
Purity:  95.94%
Target:  

FXR

Research Areas:  

Inflammation/Immunology

FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19796
CAS No.: 246529-22-6
Synonyms: Aramchol; C20-FABAC
Research Areas:  

Metabolic Disease

Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-135644
CAS No.: 1383420-08-3
Purity:  90.29%
Synonyms: CRV431
Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P2231
CAS No.: 1686108-82-6
Synonyms: MEDI0382
Target:  

GCGR

Research Areas:  

Metabolic Disease

Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P2231A
Synonyms: MEDI0382 acetate
Target:  

GCGR

Research Areas:  

Metabolic Disease

Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W011121
CAS No.: 3443-84-3
Synonyms: 2-OG
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC50 value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108022A
CAS No.: 1314533-27-1
Purity:  99.53%
Synonyms: MSDC-0602K
Target:  

Insulin Receptor PPAR

Research Areas:  

Metabolic Disease

Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .
loading...
    loading...